Afrezza: An inhaled approach to insulin delivery

Area of Science:

• Pharmacology
• Endocrinology
• Diabetes Mellitus Management

Background:

• Diabetes mellitus affects millions globally, necessitating effective insulin therapies.
• Traditional insulin delivery involves injections, which can be a barrier for some patients.
• Novel delivery systems aim to improve patient adherence and treatment outcomes.

Purpose of the Study:

• To educate nurse practitioners on Afrezza, an inhaled insulin product.
• To review the efficacy, safety, and patient satisfaction associated with Afrezza.
• To provide guidance on Afrezza's place in diabetes management.

Main Methods:

• Comprehensive literature search of MEDLINE for clinical trial data.
• Inclusion of data from CDC, WHO, clinical guidelines, and FDA labeling.
• Review of briefings and press releases related to Afrezza.

Main Results:

• Afrezza is an efficacious noninjectable insulin option for type 1 and type 2 diabetes.
• It demonstrates comparable efficacy to existing prandial insulin therapies.
• Current data suggest Afrezza is a safe alternative to injectable insulin, with high treatment satisfaction.

Conclusions:

• Afrezza presents a viable alternative for insulin-naïve patients hesitant about injections.
• Potential for less weight gain compared to subcutaneous insulin, though long-term data are needed.
• Afrezza has specific limitations and contraindications, including in type 1 diabetes, smokers, and those with lung disease.